CN105899485B - 多不饱和羟基脂肪酸的药学上可接受的盐 - Google Patents

多不饱和羟基脂肪酸的药学上可接受的盐 Download PDF

Info

Publication number
CN105899485B
CN105899485B CN201480071412.2A CN201480071412A CN105899485B CN 105899485 B CN105899485 B CN 105899485B CN 201480071412 A CN201480071412 A CN 201480071412A CN 105899485 B CN105899485 B CN 105899485B
Authority
CN
China
Prior art keywords
weight
salt
hetre
pharmaceutical composition
lysine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480071412.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN105899485A (zh
Inventor
M·曼库
D·考夫兰
B·唐斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DS Biopharma Ltd
Original Assignee
DS Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DS Biopharma Ltd filed Critical DS Biopharma Ltd
Priority to CN201811061377.2A priority Critical patent/CN109232278A/zh
Publication of CN105899485A publication Critical patent/CN105899485A/zh
Application granted granted Critical
Publication of CN105899485B publication Critical patent/CN105899485B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C241/00—Preparation of compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C241/04—Preparation of hydrazides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cosmetics (AREA)
CN201480071412.2A 2013-11-15 2014-11-17 多不饱和羟基脂肪酸的药学上可接受的盐 Expired - Fee Related CN105899485B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811061377.2A CN109232278A (zh) 2013-11-15 2014-11-17 多不饱和羟基脂肪酸的药学上可接受的盐

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361904600P 2013-11-15 2013-11-15
US61/904,600 2013-11-15
PCT/IB2014/003027 WO2015071766A1 (en) 2013-11-15 2014-11-17 Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811061377.2A Division CN109232278A (zh) 2013-11-15 2014-11-17 多不饱和羟基脂肪酸的药学上可接受的盐

Publications (2)

Publication Number Publication Date
CN105899485A CN105899485A (zh) 2016-08-24
CN105899485B true CN105899485B (zh) 2018-10-19

Family

ID=52669635

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480071412.2A Expired - Fee Related CN105899485B (zh) 2013-11-15 2014-11-17 多不饱和羟基脂肪酸的药学上可接受的盐
CN201811061377.2A Pending CN109232278A (zh) 2013-11-15 2014-11-17 多不饱和羟基脂肪酸的药学上可接受的盐

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201811061377.2A Pending CN109232278A (zh) 2013-11-15 2014-11-17 多不饱和羟基脂肪酸的药学上可接受的盐

Country Status (6)

Country Link
US (3) US10017453B2 (enExample)
EP (3) EP3068757B1 (enExample)
JP (3) JP2016538288A (enExample)
CN (2) CN105899485B (enExample)
ES (1) ES2727387T3 (enExample)
WO (1) WO2015071766A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220038818A (ko) * 2015-12-18 2022-03-29 애피뮨 리미티드 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
JP6759448B2 (ja) * 2017-03-14 2020-09-23 イビデン株式会社 植物賦活剤
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
WO2022090482A1 (en) 2020-10-30 2022-05-05 Ds Biopharma Limited Pharmaceutical compositions comprising 15-hetre and methods of use thereof
FR3148365A1 (fr) * 2023-05-04 2024-11-08 Pierre Fabre Dermo-Cosmetique Oxylipines dans le traitement de la séborrhée et/ou de l’acné

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1387503A (zh) * 1999-11-09 2002-12-25 爱尔康公司 羟基二十碳四烯酸盐,用于治疗干眼病的组合物和方法
WO2004072013A1 (ja) * 2003-02-14 2004-08-26 Taisho Pharmaceutical Co.,Ltd. ヒドロキシエイコサジエン酸化合物
CN102448453A (zh) * 2009-05-01 2012-05-09 伊奎特德有限公司 多不饱和脂肪酸在治疗神经损伤中的用途
WO2013112876A1 (en) * 2012-01-26 2013-08-01 Dignity Sciences Limited Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3055923A (en) * 1960-03-25 1962-09-25 Baxter Laboratories Inc Fatty acid salts
IE47777B1 (en) 1978-01-23 1984-06-13 Efamol Ltd Pharmaceutical and dietary composition comprising gamma-linolenic acids
JPH04507397A (ja) 1988-01-14 1992-12-24 フリッツ，アンデルス 湿疹治療用薬剤製造における必須脂肪酸の使用法
GB9111900D0 (en) 1991-06-03 1991-07-24 Efamol Holdings Fatty acid compositions
JPH05186342A (ja) 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
US5807884A (en) * 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
GB9301446D0 (en) 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
AU673700B2 (en) 1993-01-27 1996-11-21 Scotia Holdings Plc Triglycerides
US5696166A (en) * 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
HUP0102907A1 (hu) * 1996-09-20 2004-05-28 Atherogenics Inc. Gyulladásos rendellenességek diagnosztizálása és mediátorai
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
DE69927582D1 (de) * 1998-05-15 2006-02-16 Univ Vermont Burlington Neue analoga von 16-hydroxyeicosatetraensäure
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
EP1762557B1 (en) 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
US20020188024A1 (en) 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
DE10121252A1 (de) 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
EP1711173A2 (en) 2003-12-31 2006-10-18 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof
US20050239889A1 (en) 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
US7666447B2 (en) 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
US7893106B2 (en) 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
EP3581178B1 (en) 2005-02-14 2023-08-30 Suntory Holdings Limited Composition containing dihomo-(gamma)-linolenic acid (dgla) as active ingredient
TW200711649A (en) 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
EP3285072B1 (en) 2006-08-08 2020-04-15 Metabolon, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
JP5101894B2 (ja) 2007-01-15 2012-12-19 サントリーホールディングス株式会社 高度不飽和脂肪酸及びこれを含有する脂質の製造方法
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
WO2009154230A1 (ja) 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
WO2012135032A2 (en) 2011-03-25 2012-10-04 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US8936803B2 (en) 2011-10-19 2015-01-20 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
KR20140113921A (ko) 2011-11-29 2014-09-25 디그너티 사이언스 리미티드 20-탄소 지방산을 포함하는 조성물 및 이를 제조 및 사용하는 방법
CN107050457A (zh) 2012-01-06 2017-08-18 翁特拉制药公司 游离酸形式的ω‑3多不饱和脂肪酸的富含dpa组合物
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
EP2833740B1 (en) 2012-04-04 2016-09-14 Pronova BioPharma Norge AS Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
JP6370775B2 (ja) 2012-05-10 2018-08-08 ソルテックス エヌエー エルエルシー 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油
WO2014022816A2 (en) 2012-08-03 2014-02-06 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hetre and methods of treating or preventing arthritis using same
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
AU2015204531B2 (en) 2014-01-10 2019-11-14 Afimmune Limited Pharmaceutical compositions comprising 15-HEPE and methods of treating asthma and lung disorders using same
MX375328B (es) 2014-06-04 2025-03-06 Ds Biopharma Ltd Composiciones farmacéuticas que comprenden ácido dihomo-gamma-linolénico (dgla) y uso de las mismas
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
KR20220038818A (ko) 2015-12-18 2022-03-29 애피뮨 리미티드 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
CN108778266A (zh) 2016-01-07 2018-11-09 Ds生物制药有限公司 包含二高γ亚麻酸（DGLA）的医药组合物和其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1387503A (zh) * 1999-11-09 2002-12-25 爱尔康公司 羟基二十碳四烯酸盐,用于治疗干眼病的组合物和方法
WO2004072013A1 (ja) * 2003-02-14 2004-08-26 Taisho Pharmaceutical Co.,Ltd. ヒドロキシエイコサジエン酸化合物
CN102448453A (zh) * 2009-05-01 2012-05-09 伊奎特德有限公司 多不饱和脂肪酸在治疗神经损伤中的用途
WO2013112876A1 (en) * 2012-01-26 2013-08-01 Dignity Sciences Limited Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof

Also Published As

Publication number Publication date
WO2015071766A1 (en) 2015-05-21
EP3878835A1 (en) 2021-09-15
EP3546446A1 (en) 2019-10-02
JP6818851B2 (ja) 2021-01-20
EP3068757B1 (en) 2019-02-27
JP2016538288A (ja) 2016-12-08
US20180118655A1 (en) 2018-05-03
CN105899485A (zh) 2016-08-24
US20200181064A1 (en) 2020-06-11
CN109232278A (zh) 2019-01-18
US10544088B2 (en) 2020-01-28
JP2021073194A (ja) 2021-05-13
JP2020055825A (ja) 2020-04-09
US20150152034A1 (en) 2015-06-04
EP3068757A1 (en) 2016-09-21
US10017453B2 (en) 2018-07-10
ES2727387T3 (es) 2019-10-15

Similar Documents

Publication Publication Date Title
JP6818851B2 (ja) 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
KR102829415B1 (ko) 결정
CN117417263A (zh) Rad1901-2hcl的多晶型形式
ES2729824T3 (es) Formas sólidas de compuestos antirretrovirales, procedimiento para la preparación y composición farmacéutica de los mismos
CN103827122A (zh) 利福昔明的形式及其用途
WO2024179577A1 (zh) 一种Bcl-2家族蛋白降解剂的药物组合物
CN104356038B (zh) 维生素d2与d3的共晶及其制备方法和用途
WO2016078543A1 (zh) 一种盐酸洛氟普啶多晶型物及其制备方法
ES2759874T3 (es) 1,25-Dihidroxivitamina D2 estabilizada y método de preparación de la misma
JP4015954B2 (ja) トシル酸スプラタスト結晶
JP2022526478A (ja) 共結晶形エフィナコナゾール、及びその製造方法
TW202446392A (zh) 吡啶並吡唑衍生物的藥物組合物及其在醫藥上的應用
JP2013184902A (ja) リファキシミン含有結晶
HK40016232A (en) Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids
CN112538124A (zh) 一种舒更葡糖钠晶型
HK1229319B (en) Lysine salt of 15-hydroxy-8(z),11(z),13(e)-eicosatrienoic acid
HK1229319A1 (en) Lysine salt of 15-hydroxy-8(z),11(z),13(e)-eicosatrienoic acid
CN1311823C (zh) 靛玉红磷脂复合物及其制备方法
CN112574330B (zh) 一种舒更葡糖钠晶型
CN105859748B (zh) 多环化合物钠盐及其多晶型、制备方法及应用
CN116199729A (zh) 乙酰氨基阿维菌素晶型b及其制备方法
JPWO2001068587A1 (ja) スチルベン誘導体の新規結晶及びその製造方法
WO2017144010A1 (zh) (6-(1H-吲唑-6-基)-N-[4-(4-吗啉基)苯基]咪唑并[1，2-a]吡嗪-8-胺)甲磺酸盐的新晶型
WO2023174090A1 (zh) 达比加群酯共晶及其制备方法
CN118512427A (zh) 四氢姜黄素在制备治疗膀胱癌的药物中的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: Ai Erlandubailin

Patentee after: DS Biopharmaceutical Co.,Ltd.

Address before: Ai Erlandubailin

Patentee before: DS BIOPHARMA Ltd.

CP01 Change in the name or title of a patent holder
TR01 Transfer of patent right

Effective date of registration: 20210508

Address after: Ai Erlandubailin

Patentee after: DIGNITY SCIENCES LTD.

Address before: Ai Erlandubailin

Patentee before: DS Biopharmaceutical Co.,Ltd.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20181019

CF01 Termination of patent right due to non-payment of annual fee